ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
Translational Research · 2023-09 · 259 · 62-71
DOI: 10.1016/j.trsl.2023.04.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2023-09. Verfasst von Xueying An und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, State Key Laboratory of Pharmaceutical Biotechnology, Division of Sports Medicine and Adult Reconstructive Surgery,…. Hauptthemen laut MEDLINE: Methyltransferases, Osteosarcoma. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Aberrant N6-methyladenosine (m6A) modification of mRNAs contributes significantly to the epigenetic tumorigenesis, however, its precise role and the key targets in osteosarcoma (OS) are not defined. Here we reported that selective METTL3 (methyltransferase like 3) elevation and the consequential increase of m6A modification causally affect OS progression. The fast-growing OS cells displayed preferential upregulation of METTL3 and increased m6A modification. Conversely, m6A inhibition by 3-deazaadenosine, siRNA-mediated METTL3 knockdown or a METTL3-selective inhibitor STM2457 effectively inhibits OS cell growth and induced OS cell apoptosis. Further investigation revealed that an oncogenic protein ZBTB7C was likely a critical m6A target that mediated the oncogenic effects. ZBTB7C mRNA contains a typical m6A motif of high confidence and its mRNA and protein were enriched with increased m6A modification in OS samples/cells. In an OS xenograft model, STM2457 or siRNA-mediated METTL3 knockdown effectively lowed ZBTB7C abundance. More importantly, the anti-OS effects of STM2457 were significantly reduced when ZBTB7C was overexpressed by lentivirus. Together, our results demonstrate that the METTL3 aberration and the resultant ZBTB7C m6A modification form an important epigenetic regulatory loop that promotes OS progression, and targeting the METTL3/ZBTB7C axis may provide novel insights into the potential strategies for OS therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, State Key Laboratory of Pharmaceutical Biotechnology, Division of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing Unive…
- Department of Sports Medicine and Adult Reconstructive Surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China.
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
- Jiangsu Key Lab of Molecular Medicine, Nanjing University Medical School, Nanjing, China; Department of Central Laboratory, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School, The First Pe…
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
An, X., Wu, W., Yang, L., Dong, J., Liu, B., Guo, J., Chen, J., Guo, B., Cao, W., & Jiang, Q. (2023). ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression. Translational Research, 259, 62-71. https://doi.org/10.1016/j.trsl.2023.04.005
Vancouver
An X, Wu W, Yang L, Dong J, Liu B, Guo J, et al. ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression. Translational Research. 2023;259:62-71. doi:10.1016/j.trsl.2023.04.005
BibTeX
@article{An2023,
author = {An, Xueying and Wu, Wenshu and Yang, Lin and Dong, Jian and Liu, Bin and Guo, Junxia and Chen, Jianmei and Guo, Baosheng and Cao, Wangsen and Jiang, Qing},
title = {ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression},
journal = {Translational Research},
year = {2023},
volume = {259},
pages = {62--71},
doi = {10.1016/j.trsl.2023.04.005}
}
EUVIMED